Zydus Lifesciences gets USFDA nod to market generic drug

Zydus Lifesciences on Tuesday said it has received approval from the US health regulator to market a generic medication to prevent and treat blood clots. The company has received approval from the US Food and Drug Administration (USFDA) to market Apixaban tablets in strengths of 2.5 and 5 mg, according to a regulatory filing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UjCtHQw
via IFTTT